HK1207420A1 - Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia - Google Patents

Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia

Info

Publication number
HK1207420A1
HK1207420A1 HK15108002.2A HK15108002A HK1207420A1 HK 1207420 A1 HK1207420 A1 HK 1207420A1 HK 15108002 A HK15108002 A HK 15108002A HK 1207420 A1 HK1207420 A1 HK 1207420A1
Authority
HK
Hong Kong
Prior art keywords
fibromyalgia
gut
bladder
diagnosis
treatment
Prior art date
Application number
HK15108002.2A
Other languages
English (en)
Chinese (zh)
Inventor
Mark Pimentel
Christopher Chang
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of HK1207420A1 publication Critical patent/HK1207420A1/xx

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2842Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
HK15108002.2A 2012-09-17 2015-08-18 Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia HK1207420A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261701923P 2012-09-17 2012-09-17
US201361762632P 2013-02-08 2013-02-08
PCT/US2013/055626 WO2014042828A2 (fr) 2012-09-17 2013-08-19 Diagnostic et traitement de troubles de motilité de l'intestin et de la vessie et de fibromyalgie

Publications (1)

Publication Number Publication Date
HK1207420A1 true HK1207420A1 (en) 2016-01-29

Family

ID=50278832

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108002.2A HK1207420A1 (en) 2012-09-17 2015-08-18 Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia

Country Status (10)

Country Link
US (4) US9702884B2 (fr)
EP (1) EP2895856B1 (fr)
KR (1) KR102203568B1 (fr)
AU (1) AU2013315981B2 (fr)
CA (1) CA2884413C (fr)
DK (1) DK2895856T3 (fr)
ES (1) ES2646598T3 (fr)
HK (1) HK1207420A1 (fr)
MX (2) MX2015003326A (fr)
WO (1) WO2014042828A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
ES2646598T3 (es) 2012-09-17 2017-12-14 Cedars-Sinai Medical Center Diagnóstico y tratamiento de los trastornos de la motilidad del intestino y la vejiga, y de la fibromialgia
CA2962493C (fr) * 2014-10-09 2023-01-10 Cedars-Sinai Medical Center Procedes et systemes permettant de distinguer le syndrome du colon irritable de la maladie intestinale inflammatoire et de la maladie coeliaque
WO2017055467A1 (fr) * 2015-09-29 2017-04-06 Paris Sciences Et Lettres - Quartier Latin Polypeptides comprenant des sites de liaison à la vinculine pour le traitement de maladies associées à la prolifération et/ou à l'adhésion
AU2018212924A1 (en) * 2017-01-30 2019-07-04 Cedars-Sinai Medical Center Diagnosis of scleroderma
CN114895025A (zh) * 2021-07-01 2022-08-12 浙江大学 一种检测抗粘着斑蛋白-IgG抗体的试剂盒

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69133348T3 (de) 1990-10-22 2011-05-12 Centre for Digestive Diseases Pty, Ltd. Behandlung von nicht-entzündlichen darmerkrankungen
US5691151A (en) 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) * 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
US20030157159A1 (en) 2002-01-15 2003-08-21 Franklin Lanny Udell Prevention and treatment of digestive tract infections
WO2003097854A2 (fr) 2002-05-17 2003-11-27 Sugen, Inc. Nouveaux biomarqueurs d'exposition a un inhibiteur de tyrosine kinase et d'activite chez les mammiferes
WO2004019907A1 (fr) 2002-08-29 2004-03-11 Activbiotics, Inc. Procedes et reactifs pour le traitement d'infections du clostridium difficile et de maladies qui lui sont associees
US20070010434A1 (en) 2002-09-16 2007-01-11 Genetech, Inc. Novel compositions and methods for the treatment of immune related diseases
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
EP1664796B1 (fr) 2003-09-15 2010-12-15 Oklahoma Medical Research Foundation Methode d'utilisation de mesures de cytokines pour diagnostiquer, traiter et evaluer la spondylarthrite ankylosante
CA2903388C (fr) 2003-12-05 2018-01-16 Fuso Pharmaceutical Industries, Ltd. Toxines letales de distension cellulaire et detection de bacteries du genre campylobacter ciblant ces toxines
US20090233888A1 (en) 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
JP5844961B2 (ja) 2006-08-02 2016-01-20 サリックス ファーマシューティカルズ, インコーポレイテッド 放射線直腸s状結腸炎を処置するための組成物および方法
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
JP5755878B2 (ja) 2007-07-06 2015-07-29 ルパン リミテッドLupin Limited リファキシミンの薬剤組成物
EP2223121B1 (fr) * 2007-12-20 2012-07-25 Index Diagnostics AB (publ) Procédé et kit destinés à une utilisation dans la différentiation de ibd et ibs et dans la distinction complémentaire entre différents types de maladies ibd
KR20100122937A (ko) 2008-02-26 2010-11-23 샐릭스 파마슈티컬스 리미티드 장 질환의 치료 방법
GB2460717A (en) * 2008-06-11 2009-12-16 Sense Proteomic Ltd Autoantibodies for the detection of a predisposition to Lupus
KR101493125B1 (ko) 2008-11-24 2015-02-12 세다르스-신나이 메디칼 센터 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
US20110294726A1 (en) 2009-02-11 2011-12-01 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
EP2396652B1 (fr) 2009-02-11 2017-12-13 Cedars-Sinai Medical Center Procédé de diagnostic des maladies inflammatoires chroniques de l'intestin utilisant la toxine cytoléthale distendante
FR2942541A1 (fr) * 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) * 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
ES2646598T3 (es) 2012-09-17 2017-12-14 Cedars-Sinai Medical Center Diagnóstico y tratamiento de los trastornos de la motilidad del intestino y la vejiga, y de la fibromialgia
PL3054977T3 (pl) 2013-10-09 2021-12-20 Cedars-Sinai Medical Center Diagnoza i leczenie zespołu jelita drażliwego i choroby zapalnej jelit
CA2962493C (fr) 2014-10-09 2023-01-10 Cedars-Sinai Medical Center Procedes et systemes permettant de distinguer le syndrome du colon irritable de la maladie intestinale inflammatoire et de la maladie coeliaque
AU2018212924A1 (en) 2017-01-30 2019-07-04 Cedars-Sinai Medical Center Diagnosis of scleroderma

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10352944B2 (en) 2013-10-09 2019-07-16 Cedars-Sinai Medical Center Method of determinig levels of anti-vinculin and anti-cytolethal distending toxin antibodies in subjects desiring to distinguish irritable bowel syndrome from inflammatory bowel disease

Also Published As

Publication number Publication date
AU2013315981B2 (en) 2019-04-18
EP2895856A4 (fr) 2016-06-08
CA2884413A1 (fr) 2014-03-20
EP2895856B1 (fr) 2017-10-04
ES2646598T3 (es) 2017-12-14
KR102203568B1 (ko) 2021-01-15
AU2013315981A1 (en) 2015-03-26
MX2015003326A (es) 2015-08-12
US10466254B2 (en) 2019-11-05
WO2014042828A2 (fr) 2014-03-20
EP2895856A2 (fr) 2015-07-22
WO2014042828A3 (fr) 2014-10-16
KR20150058404A (ko) 2015-05-28
MX2021003764A (es) 2021-05-27
US20200271665A1 (en) 2020-08-27
US20150233944A1 (en) 2015-08-20
US20180364255A1 (en) 2018-12-20
DK2895856T3 (da) 2017-11-20
US9952223B2 (en) 2018-04-24
US20180088130A1 (en) 2018-03-29
CA2884413C (fr) 2022-11-01
US9702884B2 (en) 2017-07-11

Similar Documents

Publication Publication Date Title
IL265774B (en) Diagnosis, prevention and treatment of joint diseases
HK1221044A1 (zh) 具有醫學特徵激活的治療裝置
HK1214112A1 (zh) 非侵入式血液分析
PL3046470T3 (pl) Diagnozowanie i leczenie zaburzeń ruchu
AP2016009549A0 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
EP2861145A4 (fr) Dispositifs, systèmes et procédés pour le diagnostic et le traitement de la vessie hyperactive
EP2890440A4 (fr) Dispositifs et procédés pour le traitement d'une maladie vasculaire
EP2967744A4 (fr) Appareil de traitement de la peau
HK1207420A1 (en) Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
GB201321559D0 (en) Diagnosis of the condition of apparatus
EP3185942A4 (fr) Diagnostic, surveillance et traitement de troubles respiratoires
EP2874647A4 (fr) Procédé de diagnostic et de traitement
EP2814409A4 (fr) Traitement par ultrasons favorisé par la réflexion, et surveillance correspondante
EP2888370A4 (fr) Méthodes diagnostiques, pronostiques et méthodes de traitement
EP2726169A4 (fr) Tête de filtre, ensemble filtre et appareil de traitement d'eau comportant ceux-ci
GB2508667B (en) Diagnosis of the condition of apparatus
HK1214752A1 (zh) 由產甲烷菌引起或與之相關的疾病及病狀的診斷、選擇及治療方法
EP2958482A4 (fr) Endoscope à écarteur de pupille
EP2789289A4 (fr) Dispositif endoscopique et dispositif de traitement
HK1223983A1 (zh) 用於脊柱側凸的分類、診斷和治療的新標記
GB201415841D0 (en) Apparatuses, methods, and systems for the identification and treatment of pulmonary tissue
EP2949274A4 (fr) Dispositif de traitement cardiaque
GB201520886D0 (en) Non-invasive human condition monitoring device
GB201309645D0 (en) Treatment of peripheral arterial disease and other conditions, and apparatus therefor
GB201510676D0 (en) Novel diagnostic and therapeutic method